Slide 1: 2Q 2025 Financial Results
2Q 2025 Financial Results Nasdaq: NEO July 29, 20251
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any
Slide 3: Mission and Vision
Mission We save lives by improving patient care. Vision We are becoming the world’s leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services. 3
Slide 4: 2nd Quarter Clinical Performance
2nd Quarter Clinical Performance Clinical Volume (unit thousands) Clinical Revenue per Test Clinical Revenue ($millions) 14% Inorganic 2% Inorganic 16% Inorganic 357 $164 10% Organic 3% Organic $465 13% Organic $463 $461 $459 $150 $150 326 322 $146 $454 315 312 $141 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q2'
Slide 5: Our Strategic Drivers
Our Strategic Drivers The Customer Experience The Community Channel New Products • Continued investments in • Targeted partnerships to • Focused R&D in MRD and community oncology call point supplement current capability Therapy Selection • Investments in salesforce • Tuck-in/bolt-on acquisitions to
Slide 6: 2nd Quarter Highlights
2nd Quarter Highlights Key Takeaways • NGS revenue grew 23% over prior year Revenue Cash Flow (Ops) • Adjusted EBITDA of $11M is the 8th consecutive quarter of positive earnings $181M | 10% growth $20M | 46% growth • Adjusted Gross Profit Margin of 45.4% declined 184 bps mostly from Pathline acquisi
Slide 7: Updating FY 2025 Guidance
Updating FY 2025 Guidance Revised Guidance as of April 29th ($ Millions) YoY% Growth Guide ($ Millions) YoY% Growth Revenue $747 - $759 13 – 15 % $720 - $726 9 – 10 % $55 - $58 38 – 45 % Adj. EBIDTA $41 - $44 3 – 10 % 7
Slide 8: 2nd Quarter Financial Overview
2nd Quarter Financial Overview Financial Statement In $Millions 2Q’24 2Q’25 %vPY Revenue $164.5 $181.3 10.2% Adjusted Gross Profit $77.8 $82.4 5.9% Adjusted Gross Margin 47.3% 45.4% -184 bps Adjusted EBITDA $10.9 $10.7 -1.8% Adjusted EBITDA Margin 6.6% 5.9% -72 bps Cash and cash equivalents $355.0 $
Slide 9: Summary
Summary • Attained 16% growth in our clinical business, achieved sequential improvement in AUP, produced a record quarter for volumes, and captured NGS growth rate of 23% • Continuing macroeconomic pressure in our Non-clinical business offset Clinical strength • Neo will continue to perform as a dou
Slide 10: All rights reserved
© 2024 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. MMDDYY 10
Slide 11: Appendix
pas O c ® oe QO <x
Slide 12: Balance Sheet
June 30, 2025 (unaudited) December 31, 2024 ASSETS Current assets Balance Cash and cash equivalents $ 154,723 $ 367,012 Marketable securities, at fair value 8,962 19,832 Accounts receivable, net 153,125 150,540 Sheet Inventories 34,171 26,748 Prepaid assets 22,831 20,165 Other current assets 9,785 1
Slide 13: Income Statement
Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 NET REVENUE $ 181,330 $ 164,502 $ 349,365 $ 320,742 Income COST OF REVENUE 104,072 92,008 198,861 182,779 Statement GROSS PROFIT 77,258 72,494 150,504 137,963 Operating expenses: General and administrative 71,747 63,328 139,95
Slide 14: Statements of Cash Flows
Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (71,015) $ (45,703) Statements of Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 18,506 19,651 Cash Flows Amortization of intangibles 16,486 16,723 Stock-based compensation 2
Slide 15: Adjusted Gross Margin
Three Months Ended June 30, Six Months Ended June 30, % % 2025 2024 Change 2025 2024 Change Adjusted Consolidated: Total revenue (GAAP) $ 181,330 $ 164,502 10.2% $ 349,365 $ 320,742 8.9% Gross Margin June 30, 2025 Cost of revenue (GAAP) $ 104,072 $ 92,008 13.1% $ 198,861 $ 182,779 8.8% Adjustments t
Slide 16: Adjusted EBITDA
Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Adjusted Net loss (GAAP) $ (45,092) $ (18,642) $ (71,015) $ (45,703) Adjustments to net loss: Interest income (2,263) (4,592) (5,984) (9,426) EBITDA Interest expense Income tax benefit 933 (724) 1,666 (375) 2,551 (458) 3,351 (
Slide 17: Adjusted EBITDA 2025 Guidance
Year Ended December 31, 2025 Low Range High Range Adjusted Net loss (GAAP) $ (116,00) $(108,000) Amortization of intangibles 32,000 32,000 Stock-based compensation expenses 46,000 43,000 EBITDA Other one-time expenses 48,000 48,000 Adjusted net income (non-GAAP) 10,000 15,000 Interest and taxes (7,0